VGX-1027
(Synonyms: GIT 27) 目录号 : GC10210
An immunomodulatory compound
Cas No.:6501-72-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
VGX-1027 is a potent immunomodulatory agent [1].
Immunotherapy refers to treatment of disease by suppressing, inducing or enhancing an immune response.
VGX-1027 is an isoxazoline compound with potent immunomodulatory properties [1]. In microarray analysis, VGX-1027 modulated the expression of genes that involved in immune activation and the antigen processing and presentation in response to lipopolysaccharide (LPS) stimulation [2]. In CD4+CD25− T cells, VGX-1027 inhibited cell proliferation induced by enterobacterial antigen [3].
In NOD mice with spontaneous or accelerated diabetes, VGX-1027 significantly reduced the incidence of insulitis and diabetes. In CBA/H mice, VGX-1027 significantly inhibited the development of hyperglycemia and destructive insulitis induced by multiple low doses of streptozotocin. Also, VGX-1027 inhibited the production of inducible nitric-oxide synthase-mediated nitric oxide, macrophage migration inhibitory factor, proinflammatory mediators tumor necrosis factor-α and IL-1β in pancreatic islets [1]. In NZB/NZW F1 mice with systemic lupus erythematosus (SLE), VGX-1027 ameliorated the disease and increased survival [2]. In mice with acute inflammatory colitis, VGX-1027 inhibited the development of colitis. Also, VGX-1027 reduced the production of proinflammatory cytokines TNF-α, IL-12p70, interleukin (IL)-1β, interferon (IFN)-γ and nuclear factor NF-κB (p65) [3].
References:
[1]. Stosic-Grujicic S, Cvetkovic I, Mangano K, et al. A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. J Pharmacol Exp Ther, 2007, 320(3): 1038-1049.
[2]. Fagone P, Muthumani K, Mangano K, et al. VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus. Immunology, 2014, 142(4): 594-602.
[3]. Mangano K, Sardesai N, D'Alcamo M, et al. In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. Eur J Pharmacol, 2008, 586(1-3): 313-321.
| Cas No. | 6501-72-0 | SDF | |
| 别名 | GIT 27 | ||
| 化学名 | 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid | ||
| Canonical SMILES | C1C(ON=C1C2=CC=CC=C2)CC(=O)O | ||
| 分子式 | C11H11NO3 | 分子量 | 205.21 |
| 溶解度 | DMF: 20 mg/ml,DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml,DMSO: 15 mg/ml,Ethanol: 10 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.8731 mL | 24.3653 mL | 48.7306 mL |
| 5 mM | 0.9746 mL | 4.8731 mL | 9.7461 mL |
| 10 mM | 0.4873 mL | 2.4365 mL | 4.8731 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet